通过天眼查大数据分析，漳州片仔癀药业股份有限公司共对外投资了26家企业，参与招投标项目840 次，知识产权方面有商标信息320条，专利信息304条，此外企业还拥有行政许可239个。 来源：金融界 资金流向方面，今日主力资金净流入3546.75万元，占比成交额6.02%。其中，超大单净流入73.54万 元、占成交额0.12%，大单净流入3473.21万元、占成交额5.89%，中单净流出流入330.90万元、占成交 额0.56%，小单净流出3877.65万元、占成交额6.58%。 金融界消息 截至2025年8月15日收盘，片仔癀（600436）报收于200.93元，下跌0.5%，换手率0.49%， 成交量2.93万手，成交金额5.90亿元。 片仔癀最新一期业绩显示，截至2025一季报，公司营业总收入31.42亿元、同比减少0.92%，归属净利润 10.00亿元，同比增长2.59%，扣非净利润10.05亿元，同比增长1.69%，流动比率5.240、速动比率 3.112、资产负债率14.29%。 天眼查商业履历信息显示，漳州片仔癀药业股份有限公司，成立于1999年，位于漳州市，是一家以从事 医药制造业为主的企业。企业 ...

Core Viewpoint - The recent personnel changes at Pianzaihuang Pharmaceutical Co., Ltd. reflect an effort to improve corporate governance and operational efficiency amidst declining financial performance and market challenges [1][3]. Personnel Changes - Pianzaihuang announced the appointment of He Wei as Vice General Manager and Wei Tengyun as Chief Engineer, both with relevant experience and qualifications [1]. - The company also restructured its Board of Directors' Audit Committee, replacing previous members to ensure effective functioning [1]. - Earlier this year, the company saw the resignation of several executives, including Vice General Managers Chen Honghui and Hong Fei, with Shi Yixiong being appointed as a new Vice General Manager [2]. Financial Performance - In Q1 2025, Pianzaihuang reported a revenue of 3.142 billion yuan, a year-on-year decrease of 0.92%, while net profit increased by 2.59% to 1 billion yuan [3]. - For the full year 2024, the company achieved a revenue of 10.788 billion yuan, a growth of 7.25%, and a net profit of 2.977 billion yuan, up 6.42% [3]. - The revenue growth rate for 2024 was the lowest in a decade, and Q4 2024 marked the worst quarterly performance since 2020, with a revenue drop of 4.92% [3]. Market Dynamics - The company's previous success was largely driven by the high market price of its flagship product, which has seen a significant price drop from 1,600 yuan to as low as 590 yuan, impacting revenue [4]. - The decline in product prices, which fell nearly 40% within a year, is a direct cause of the company's financial struggles [4]. - Rising costs of key raw materials, such as cow bile, are expected to exert further pressure on the company's profitability [4]. - In response to declining performance, Pianzaihuang is exploring diversification into the beauty industry to sustain growth [4].

Market Overview - The Shanghai Composite Index closed at 3666.44 points, above the six-month moving average, with a decline of 0.46% [1] - The total trading volume of A-shares reached 23062.83 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 21 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Haiguang Information: 6.29% - AVIC Optoelectronics: 3.02% - Hongjing Technology: 3.01% [1] Detailed Stock Performance - The following stocks showed notable performance: - Haiguang Information (688041): Increased by 8.83% with a turnover rate of 3.39%, latest price at 152.49 yuan [1] - AVIC Optoelectronics (002179): Increased by 4.15% with a turnover rate of 3.55%, latest price at 40.66 yuan [1] - Hongjing Technology (301396): Increased by 4.98% with a turnover rate of 21.13%, latest price at 59.48 yuan [1] - Other stocks with smaller deviation rates include: - Sichuan Road and Bridge (600039): Increased by 0.72% with a turnover rate of 0.94%, latest price at 8.42 yuan [2] - Jike Technology (835579): Increased by 2.49% with a turnover rate of 10.49%, latest price at 29.66 yuan [2]

Board Changes - The company announced the resignation of Mr. Lai Wenning from the board of directors due to work adjustments, effective immediately upon delivery of his resignation [2][3] - The resignation of Mr. Lai did not result in the board having fewer members than legally required, ensuring normal operations continue [3] - The company expressed gratitude for Mr. Lai's contributions during his tenure [3] Supervisor Changes - The company received resignation letters from employee supervisors Mr. Wei Tengyun and Ms. Huang Qiumin, also due to work adjustments [2][4] - Their resignations did not affect the legal number of members in the supervisory board, allowing for continued normal operations [4] - The company thanked both supervisors for their diligent service during their tenure [4] Board Meeting Resolutions - The company's seventh board of directors held its 32nd meeting on August 13, 2025, with all seven directors present [6] - The board approved the appointment of Mr. He Wei as the new deputy general manager, with his term aligned with the current board's term [6][9] - The board also approved the appointment of Mr. Wei Tengyun as the new chief engineer, with his term also aligned with the current board's term [9] - The board made adjustments to the audit committee, maintaining its legal composition [11][13]

证券代码：600436 证券简称：片仔癀 公告编号：2025-025 漳州片仔癀药业股份有限公司 第七届董事会第三十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 漳州片仔癀药业股份有限公司（以下简称"公司"）第七届董事 会第三十二次会议于 2025 年 8 月 13 日（星期三）上午 9：00 在公司 片仔癀大厦 23 楼会议室以通讯方式召开。会议通知和议案以专人送 达、电子邮件方式发出。本次会议应参加表决董事 7 人，实际表决的 董事 7 人。会议召开符合《公司法》与《漳州片仔癀药业股份有限公 司章程》 （以下简称" 《公司章程》 "）的有关规定，合法、有效，会议 由董事长林志辉先生主持。经审议，与会董事以通讯方式表决以下决 议： 一、审议通过《公司关于聘任副总经理的议案》 ； 出席会议的董事 7 票同意，0 票反对，0 票弃权。 为完善公司治理结构，经控股股东推荐，总经理黄进明先生提名， 经董事会提名委员会审议通过，同意聘任何炜先生为公司副总经理 （简历附后）。任期与第七届董事会任期一致。 本议案已经董 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-024 漳州片仔癀药业股份有限公司 关于公司董事、监事变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事变动情况 | | | | | 是否继续在 具体职 | | 是否存在 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 离任 | | 原定任期 | 离任 | 上市公司及 | | 未履行完 | | 姓名 | | 离任时间 | | | 务（如 | | | | | 职务 | | 到期日 | 原因 | 其控股子公 | | 毕的公开 | | | | | | | 适用） | | | | | | | | 司任职 | 承诺 | | | | 赖文宁 | 董事 | | | 否 | / | 否 | | 月 13 日 月 20 日 调整 根据《中华人民共和国公司法》《漳州片仔癀药业股份有限公司 章程》 漳州片仔癀药业股份有限公司（以下简称"公司" ）董事会于近 日收到董事赖文宁先生提交的书面辞职报告。赖文宁 ...

Group 1 - The core point of the article is that the company Pianzaihuang announced the approval of multiple proposals, including the appointment of a new vice president during the 32nd meeting of its seventh board of directors [2] Group 2 - The announcement was made on the evening of August 13, indicating the company's ongoing governance activities [2] - The meeting involved significant decisions that may impact the company's management structure and operational strategy [2]

证券日报网讯8月13日晚间，片仔癀（600436）发布公告称，公司董事会于近日收到董事赖文宁先生提 交的书面辞职报告。赖文宁先生因工作调整原因，辞去公司董事及董事会下属审计委员会委员等职务。 辞职后，赖文宁先生不再担任公司的任何职务。 ...

（文章来源：每日经济新闻） 片仔癀8月13日晚间发布公告称，赖文宁先生因工作调整原因，辞去公司董事及董事会下属审计委员会 委员等职务。赖文宁先生不再担任公司的任何职务。魏腾云先生、黄秋敏女士因工作调整原因，辞去公 司监事职务。 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-024 漳州片仔癀药业股份有限公司 关于公司董事、监事变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事变动情况 漳州片仔癀药业股份有限公司（以下简称"公司"）董事会于近 日收到董事赖文宁先生提交的书面辞职报告。赖文宁先生因工作调整 原因，辞去公司董事及董事会下属审计委员会委员等职务。辞职后， 赖文宁先生不再担任公司的任何职务。 | 姓名 | 离任 | 离任时间 | | 原定任期 | | 离任 | 是否继续在 上市公司及 | 具体职 务（如 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 职务 | | | 到期日 | | 原因 | 其控股子公 | 适用） | 毕的公开 | | | | | | | | | 司任职 | | 承诺 | | 赖文宁 | 董事 | 2025 | 年 8 | 2025 1 | 年 | 工作 | 否 | / | 否 | ...